CRME - Cardiome Pharma Corp.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.47
+0.04 (+2.80%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close1.43
Open1.45
Bid1.35 x 300
Ask1.85 x 3900
Day's Range1.44 - 1.48
52 Week Range1.29 - 4.84
Volume12,563
Avg. Volume84,380
Market Cap49.39M
Beta-0.21
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.91
Trade prices are not sourced from all markets
  • Best TSX Growth Stocks
    Simply Wall St.5 days ago

    Best TSX Growth Stocks

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • PR Newswire12 days ago

    Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

    NASDAQ:CRME  TSX:COM VANCOUVER , Feb. 8, 2018 /PRNewswire/ -   Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • CNW Group12 days ago

    Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

    Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

  • Zacks Small Cap Research15 days ago

    CRME: Initiating Coverage

    Through its acquisition of Correvio in late 2013, Cardiome procured a salesforce, EU licenses and worldwide sales rights (ex-US) for Aggrastat.  This action provided immediate sales and infrastructure to commercialize the internally developed Brinavess as well as the structure necessary to layer on additional products.  Following this initial transaction, Cardiome has obtained the rights to four other products, including two complementary anti-infectives. Based on our forecasts which include revenues for currently licensed drugs and a probability-weighted contribution from Trevyent, we expect breakeven on an operational basis in 2020.  This forecast assumes growth in all products, with a greater contribution from Xydalba and Zevtera in 2018 and initial contribution from Trevyent in 2020.

  • CNW Group28 days ago

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

  • PR Newswire28 days ago

    Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

    Addition of High-Risk STEMI Patients Significantly Expands the Number of Patients in Which Aggrastat Can Be Used NASDAQ:CRME  TSX:COM VANCOUVER , Jan. 23, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME ...

  • CNW Grouplast month

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

  • PR Newswirelast month

    Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

    NASDAQ:CRME TSX:COM VANCOUVER , Jan. 10, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • PR Newswire2 months ago

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    VANCOUVER, Dec. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia. Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide. Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

  • CNW Group2 months ago

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

  • With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?
    Simply Wall St.2 months ago

    With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?

    After looking at Cardiome Pharma Corp’s (TSX:COM) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • PR Newswire2 months ago

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (STDY) has reached agreement with the U.S. Food and Drug Administration (FDA) on the work necessary to resubmit the New Drug Application (NDA) for Trevyent® for the treatment of pulmonary arterial hypertension (PAH). Based on written feedback received from the FDA, SteadyMed indicated that is not required to conduct any clinical trials to prove the safety or efficacy of Trevyent and that the FDA has agreed that certain in vitro design verification (DV) tests on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and process validation, should be adequate for the resubmission and acceptance of the 505(b)(2) NDA.

  • CNW Group2 months ago

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

  • PR Newswire2 months ago

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy (OPAT) Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December 11-12, 2017 in Birmingham, UK. The Company-sponsored plenary symposium, titled, "Managing serious skin infections within the changing NHS, time for a rethink?" will feature presentations by three physician experts describing treatment and patient experience with Cardiome's Xydalba™ (dalbavancin hydrochloride), the first and only 30-minute, one-dose treatment option for acute bacterial skin and skin structure infections. Cardiome currently markets Xydalba in France, Germany, the UK, the Republic of Ireland, Belgium, Finland and Sweden.

  • CNW Group2 months ago

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

  • PR Newswire3 months ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    VANCOUVER, Nov. 20, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz, Chief Financial Officer of Cardiome, will present at the 29th Annual Piper Jaffray Healthcare Conference. The presentation will take place at the Lotte New York Palace on Tuesday, November 28, 2017 at 2:30 p.m. EDT.

  • CNW Group3 months ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

  • Associated Press3 months ago

    Cardiome reports 3Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 20 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by ...

  • CNW Group3 months ago

    Cardiome Reports Third Quarter 2017 Financial Results

    Cardiome Reports Third Quarter 2017 Financial Results

  • PR Newswire3 months ago

    Cardiome Reports Third Quarter 2017 Financial Results

    NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, November 14, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME ...

  • ACCESSWIRE3 months ago

    Cardiome Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Cardiome Pharma Corp. (NASDAQ: CRME ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 4:30 ...

  • PR Newswire3 months ago

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    VANCOUVER, Nov. 7, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that it will report financial results for the third quarter ended September 30, 2017 on Tuesday, November 14, 2017. Cardiome will hold a conference call and webcast at 4:30 p.m. Eastern (1:30 p.m. Pacific) on that day to discuss the results. To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 66802456.

  • CNW Group3 months ago

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

  • What’s Installed For Cardiome Pharma Corp (TSX:COM)?
    Simply Wall St.3 months ago

    What’s Installed For Cardiome Pharma Corp (TSX:COM)?

    Cardiome Pharma Corp (TSX:COM), a CADCA$70.60M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...